Thus, increased understanding of how the regulation of CaMKII contributes to the arrhythmogenic phenotype in CPVT might help develop new treatment strategies to prevent arrhythmias, while preserving the physiological effects of CaMKII. This evidence concerns the gene CAMK2G and catecholaminergic polymorphic ventricular tachycardia.